Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603432 · ClinicalTrials.gov registry record · Phase 3
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
A Phase 3 study of Urothelial Cancer, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
- 20
- Study locations
NCT02603432 is a Phase 3 study of Urothelial Cancer that has completed, run by Pfizer. The registered enrollment target is 700 participants, above the 546-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT02603432, a Phase 3 study of Urothelial Cancer, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy.
Conditions Studied
Interventions
- BIOLOGICAL Avelumab
- OTHER Best Supportive Care
- BIOLOGICAL Following the planned interim analysis for this study: Avelumab
Study Locations (20)
Colorado
- Anschutz Cancer Center Pavilion Pharmacy - Aurora
- University of Colorado Cancer Center - Aurora
- University of Colorado Denver, CTO (CTRC) - Aurora
- University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) - Aurora
- University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) - Aurora
Ohio
- Cleveland Clinic Taussing Cancer Center - Cleveland
- Cleveland Clinic Taussing Cancer Center - Cleveland
- Cleveland Clinic Foundation - Cleveland
- Cleveland Clinic Taussing Cancer Center - Cleveland
Washington
- Seattle Cancer Care Alliance - Seattle
- Seattle Cancer Care Alliance - Seattle
- University of Washington Medical Center - Seattle
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
- Smilow Cancer Hospital at Yale-New Haven - New Haven
Minnesota
- University of Minnesota Medical Center - Minneapolis
- University of Minnesota - Minneapolis
Virginia
- Inova Schar Cancer Institute Infusion Pharmacy - Fairfax
- Inova Schar Cancer Institute - Fairfax
Massachusetts
- Massachusetts General Hospital - Boston
Buenos Aires
- Centro de Investigacion Pergamino S.A. - Pergamino
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2016-04-25 |
| Est. Completion | 2023-03-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02603432
The ClinicalTrials.gov registry entry for NCT02603432 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 546-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (28% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urothelial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Avelumab is the first listed.
NCT02603432 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Colorado, Ohio, Washington.
Frequently Asked Questions
What is clinical trial NCT02603432 about?
NCT02603432 is a clinical study titled "A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)". The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of ...
What is the current status of trial NCT02603432?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2016-04-25. Estimated completion is 2023-03-28.
What conditions does trial NCT02603432 study?
This clinical trial studies the following conditions: Urothelial Cancer.
What interventions are being tested in trial NCT02603432?
The interventions under investigation include: Avelumab (BIOLOGICAL), Best Supportive Care (OTHER), Following the planned interim analysis for this study: Avelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02603432?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02603432 being conducted?
This trial has 20 study locations across Colorado, Connecticut, Massachusetts, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
ACTIVE NOT RECRUITING · Phase 3
-
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
ACTIVE NOT RECRUITING · Phase 3
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.